Management of endocrine disease: secondary osteoporosis: pathophysiology and management

F Mirza, E Canalis - European journal of endocrinology, 2015 - academic.oup.com
Osteoporosis is a skeletal disorder characterized by decreased mass and compromised
bone strength predisposing to an increased risk of fractures. Although idiopathic …

Vitamin D deficiency, osteoporosis and effect on autoimmune diseases and hematopoiesis: a review

M De Martinis, A Allegra, MM Sirufo, A Tonacci… - International journal of …, 2021 - mdpi.com
Vitamin D (VD) is essential for bone homeostasis, but it is also involved in pleiotropic effects
on various organs and tissues. In adults, VD deficiency can cause or exacerbate …

International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease

E Terpos, G Morgan, MA Dimopoulos… - Journal of clinical …, 2013 - ascopubs.org
Purpose The aim of the International Myeloma Working Group was to develop practice
recommendations for the management of multiple myeloma (MM)–related bone disease …

Monoclonal gammopathy of undetermined significance

TH Mouhieddine, LD Weeks… - Blood, The Journal of …, 2019 - ashpublications.org
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma
cell dyscrasia that consistently precedes multiple myeloma (MM) with a 1% risk of …

Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

E Terpos, E Zamagni, S Lentzsch, MT Drake… - The Lancet …, 2021 - thelancet.com
Summary In this Policy Review, the Bone Working Group of the International Myeloma
Working Group updates its clinical practice recommendations for the management of …

[HTML][HTML] The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the …

NWCJ van de Donk, A Palumbo, HE Johnsen… - …, 2014 - ncbi.nlm.nih.gov
Monoclonal gammopathy of undetermined significance is one of the most common pre-
malignant disorders. IgG and IgA monoclonal gammopathy of undetermined significance are …

The microenvironment in myeloma

OC Lomas, S Tahri, IM Ghobrial - Current opinion in oncology, 2020 - journals.lww.com
Multiple myeloma is rarely curable and its interactions with the bone marrow
microenvironment are evident. However, separating cause from effect remains a challenge …

The global prevalence of vitamin D deficiency and insufficiency in patients with multiple myeloma: A systematic review and meta-analysis

NH Ismail, A Mussa, MJ Al-Khreisat, S Mohamed Yusoff… - Nutrients, 2023 - mdpi.com
Background: Multiple myeloma (MM) is a hematological malignancy characterized by the
exponential growth of malignant plasma cells. Individuals diagnosed with MM exhibit a …

The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies

H Zhang, JL Liesveld, LM Calvi, BC Lipe, L Xing… - Bone Research, 2023 - nature.com
Prior research establishing that bone interacts in coordination with the bone marrow
microenvironment (BMME) to regulate hematopoietic homeostasis was largely based on …

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

TE Witzig, KM Laumann, MQ Lacy, SR Hayman… - Leukemia, 2013 - nature.com
Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of
transformation to active multiple myeloma (MM). Bisphosphonates such as zoledronic acid …